According to a newly published market research report by 24LifeSciences, global single-use technologies for biologics market was valued at USD 4.79 billion in 2024 and is projected to reach USD 9.59 billion by 2031, growing at a compound annual growth rate (CAGR) of 10.7% during the forecast period 2025-2031.

Single-use technologies (SUT) represent innovative disposable bioprocessing systems including bioreactors, filtration assemblies, and fluid management solutions designed for one-time applications in biologic manufacturing. These systems have become essential for modern biopharmaceutical production, offering contamination prevention, operational flexibility, and reduced capital expenditure compared to traditional stainless steel systems. Their adoption has transformed biologics manufacturing across monoclonal antibodies, vaccines, and cell/gene therapies.

Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/15937/single-use-technologies-for-the-biologic-market

Biopharmaceutical Industry Expansion Drives Market Adoption

The rapid growth of the biologics sector, expected to expand at 8.4% CAGR through 2030, serves as the primary catalyst for single-use technology adoption. These disposable systems enable faster facility build-outs, multi-product flexibility, and reduced validation requirements - critical advantages as manufacturers respond to increasing demand for complex therapies. The pandemic particularly highlighted the value of single-use systems through their ability to accelerate vaccine production scale-up by 30-40% compared to traditional systems.

Furthermore, single-use technologies significantly lower contamination risks in sensitive biologic processes while reducing water and energy consumption by up to 50%, making them increasingly attractive from both operational and sustainability perspectives.

Technological Innovations Enhance Single-Use Capabilities

Recent advancements in polymer science and sensor integration have dramatically improved single-use system performance. Manufacturers now offer single-use bioreactors with capacities up to 2000L, advanced mixing systems with integrated analytics, and specialized membrane adsorbers for downstream purification. These innovations enable end-to-end single-use processing trains capable of handling most clinical and commercial-scale biologics production.

Moreover, the integration of single-use technologies with continuous bioprocessing represents a significant industry shift toward more efficient manufacturing paradigms. Major biopharma companies are increasingly adopting hybrid models that combine single-use components with automated control systems.

Market Challenges: Scaling Limitations and Supply Chain Pressures

Despite strong growth, the single-use technologies market faces several notable constraints:

• Scalability bottlenecks for large-volume commercial production exceeding 2000L

• Supply chain vulnerabilities for critical plastic components and filter materials

• Extractables/leachables concerns requiring extensive validation studies

• Higher per-unit costs compared to reusable systems at full utilization

Additionally, the industry continues working to improve standardization across connectors, sensors, and quality testing protocols to facilitate wider adoption.

Get the Complete Report & Table of Contents: https://www.24lifesciences.com/single-use-technologies-for-the-biologic-market-15937

North America Leads Global Adoption with Asia-Pacific Showing Strongest Growth

The North American market accounts for approximately 38% of global single-use technology revenues, driven by advanced biopharma R&D infrastructure and regulatory support for innovative manufacturing approaches. However, the Asia-Pacific region is projected to grow at 13.2% CAGR through 2031, fueled by expanding biologics production in China, India, and South Korea.

Key adoption drivers across regions include:

• Government initiatives supporting local biomanufacturing capabilities

• Growing preference for modular facility designs

• Increasing demand for biosimilars and vaccines

• Need for flexible multi-product manufacturing

Europe maintains strong adoption through its established biopharma industry and environmental regulations favoring disposable systems.

Bioreactors and Filtration Systems Dominate Product Segments

Within the single-use technologies market, bioreactors represent the largest product category due to their central role in biologics production, showing 12.3% CAGR growth. These systems now incorporate advanced sensors and controls matching traditional bioreactor capabilities. Meanwhile, membrane adsorbers and tangential flow filtration systems are gaining traction for downstream processing efficiency.

By application, monoclonal antibody production accounts for the majority share, though vaccines and cell/gene therapies demonstrate the fastest growth rates as these therapies increasingly adopt single-use platforms.

Competitive Landscape: Consolidated Market with Strategic Partnerships

The global single-use technologies market is moderately consolidated, with the top three players controlling approximately 40% of market share. Competition centers on technology innovation, global service networks, and strategic alliances with biopharma companies. Recent years have seen significant M&A activity as major players expand their single-use system portfolios.

Key companies profiled in the report include:

• Thermo Fisher Scientific

• Sartorius AG

• Danaher Corporation

• Merck Millipore

• Corning Incorporated

• Pall Corporation

• Repligen Corporation

• and More

Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/single-use-technologies-for-the-biologic-market-15937

Emerging Opportunities in Cell/Gene Therapy and Sustainability

Significant growth potential exists in specialized single-use solutions for cell/gene therapies, where contamination risk management is paramount. Additionally, increasing focus on sustainability is driving development of recyclable and biodegradable single-use components, opening new avenues for eco-conscious biomanufacturing.

The continued expansion of contract manufacturing organizations and emerging market biopharma producers presents substantial opportunities, as these segments particularly value the flexibility and lower capital requirements of single-use systems.

Access the Full Report

Download a Free Sample Report (PDF):
https://www.24lifesciences.com/download-sample/15937/single-use-technologies-for-the-biologic-market

Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/single-use-technologies-for-the-biologic-market-15937

About 24LifeSciences

24LifeSciencesis a leading provider of market intelligence and strategic research reports across pharmaceuticals, biotechnology, medical devices, and healthcare technologies. Our reports are designed to support data-driven decision-making for manufacturers, healthcare providers, investors, consultants, and policy makers worldwide.

Follow us on LinkedIn:
https://www.linkedin.com/company/lifesciences24/